Review of the risk of cancer following low and moderate doses of sparsely ionising radiation received in early life in groups with individually estimated doses.


Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
15 01 2022
Historique:
received: 25 02 2021
revised: 16 10 2021
accepted: 13 11 2021
pubmed: 28 12 2021
medline: 17 3 2022
entrez: 27 12 2021
Statut: ppublish

Résumé

The detrimental health effects associated with the receipt of moderate (0.1-1 Gy) and high (>1 Gy) acute doses of sparsely ionising radiation are well established from human epidemiological studies. There is accumulating direct evidence of excess risk of cancer in a number of populations exposed at lower acute doses or doses received over a protracted period. There is evidence that relative risks are generally higher after radiation exposures in utero or in childhood. We reviewed and summarised evidence from 60 studies of cancer or benign neoplasms following low- or moderate-level exposure in utero or in childhood from medical and environmental sources. In most of the populations studied the exposure was predominantly to sparsely ionising radiation, such as X-rays and gamma-rays. There were significant (p < 0.001) excess risks for all cancers, and particularly large excess relative risks were observed for brain/CNS tumours, thyroid cancer (including nodules) and leukaemia. Overall, the totality of this large body of data relating to in utero and childhood exposure provides support for the existence of excess cancer and benign neoplasm risk associated with radiation doses < 0.1 Gy, and for certain groups exposed to natural background radiation, to fallout and medical X-rays in utero, at about 0.02 Gy.

Sections du résumé

BACKGROUND
The detrimental health effects associated with the receipt of moderate (0.1-1 Gy) and high (>1 Gy) acute doses of sparsely ionising radiation are well established from human epidemiological studies. There is accumulating direct evidence of excess risk of cancer in a number of populations exposed at lower acute doses or doses received over a protracted period. There is evidence that relative risks are generally higher after radiation exposures in utero or in childhood.
METHODS AND FINDINGS
We reviewed and summarised evidence from 60 studies of cancer or benign neoplasms following low- or moderate-level exposure in utero or in childhood from medical and environmental sources. In most of the populations studied the exposure was predominantly to sparsely ionising radiation, such as X-rays and gamma-rays. There were significant (p < 0.001) excess risks for all cancers, and particularly large excess relative risks were observed for brain/CNS tumours, thyroid cancer (including nodules) and leukaemia.
CONCLUSIONS
Overall, the totality of this large body of data relating to in utero and childhood exposure provides support for the existence of excess cancer and benign neoplasm risk associated with radiation doses < 0.1 Gy, and for certain groups exposed to natural background radiation, to fallout and medical X-rays in utero, at about 0.02 Gy.

Identifiants

pubmed: 34959181
pii: S0160-4120(21)00608-5
doi: 10.1016/j.envint.2021.106983
pmc: PMC9118883
mid: NIHMS1763948
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

106983

Subventions

Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States

Informations de copyright

Published by Elsevier Ltd.

Références

Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):804-806
pubmed: 28052939
Environ Health Perspect. 2011 Jul;119(7):933-9
pubmed: 21406336
Occup Environ Med. 2009 Dec;66(12):789-96
pubmed: 19570756
Int J Epidemiol. 2019 Apr 1;48(2):379-381g
pubmed: 30388267
Radiat Res. 1994 Dec;140(3):327-33
pubmed: 7972684
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Radiat Environ Biophys. 2017 May;56(2):127-138
pubmed: 28337585
Int J Epidemiol. 2006 Apr;35(2):386-96
pubmed: 16269548
Radiat Res. 2007 Jul;168(1):1-64
pubmed: 17722996
J Radiat Res. 2020 Mar 23;61(2):243-248
pubmed: 32030428
Radiat Res. 2010 Jul;174(1):83-90
pubmed: 20681802
Epidemiology. 2016 May;27(3):316-22
pubmed: 26441345
Neuroepidemiology. 2020;54(4):343-355
pubmed: 32200380
Radiat Res. 2017 May;187(5):538-548
pubmed: 28323575
Semin Fetal Neonatal Med. 2014 Jun;19(3):203-13
pubmed: 24378676
Ann ICRP. 2007;37(2-4):1-332
pubmed: 18082557
Int J Radiat Biol. 2018 Nov;94(11):1017-1026
pubmed: 30028637
JNCI Cancer Spectr. 2018 Oct;2(4):pky081
pubmed: 31249993
Environ Health Perspect. 2004 May;112(6):766-71
pubmed: 15121523
Leukemia. 2013 Jan;27(1):3-9
pubmed: 22766784
JAMA. 2004 Dec 1;292(21):2600-13
pubmed: 15572718
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6
pubmed: 14610281
J Radiol Prot. 2021 Jun 01;41(2):
pubmed: 33571972
J Clin Epidemiol. 1990;43(5):449-60
pubmed: 2324785
Lancet. 1988 Sep 17;2(8612):665-9
pubmed: 2901525
Br Med J. 1958 Jun 28;1(5086):1495-508
pubmed: 13546604
Radiat Environ Biophys. 2021 Aug;60(3):485-491
pubmed: 34218328
Environ Health Perspect. 2015 Jun;123(6):622-8
pubmed: 25707026
Radiat Environ Biophys. 2021 Aug;60(3):493-500
pubmed: 34170393
Br J Cancer. 1990 Jul;62(1):152-68
pubmed: 2202420
J Natl Cancer Inst Monogr. 2020 Jul 1;2020(56):97-113
pubmed: 32657348
J Natl Cancer Inst Monogr. 2020 Jul 1;2020(56):133-153
pubmed: 32657349
J Natl Cancer Inst. 2005 May 18;97(10):724-32
pubmed: 15900042
Health Phys. 2019 Feb;116(2):235-246
pubmed: 30585971
Radiat Prot Dosimetry. 2008;132(2):166-74
pubmed: 18922822
Lancet Haematol. 2018 Aug;5(8):e346-e358
pubmed: 30026010
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2575-2583
pubmed: 28323979
J Radiol Prot. 2020 Aug 06;:
pubmed: 32759481
Ann ICRP. 2015 Jun;44(1 Suppl):236-48
pubmed: 25816281
J Natl Cancer Inst. 1962 May;28:1173-91
pubmed: 14468031
J Natl Cancer Inst Monogr. 2020 Jul 1;2020(56):176-187
pubmed: 32657345
J Natl Cancer Inst Monogr. 2020 Jul 1;2020(56):114-132
pubmed: 32657346
Fertil Steril. 2015 Aug;104(2):452-9.e2
pubmed: 26051091
Br J Cancer. 2008 Aug 5;99(3):545-50
pubmed: 18665174
J Natl Cancer Inst Monogr. 2020 Jul 1;2020(56):154-175
pubmed: 32657350
Am J Epidemiol. 2022 Jan 1;191(1):173-181
pubmed: 34642734
JAMA. 2019 Sep 3;322(9):843-856
pubmed: 31479136
Eur J Epidemiol. 2017 Dec;32(12):1047-1054
pubmed: 28929329
Br J Cancer. 2015 Jan 6;112(1):185-93
pubmed: 25314057
Int J Cancer. 2016 Nov 1;139(9):1975-82
pubmed: 27405274
Int J Radiat Biol. 2003 May;79(5):293-309
pubmed: 12943238
Radiat Res. 2004 Apr;161(4):373-9
pubmed: 15038761
Stat Med. 1988 Aug;7(8):857-64
pubmed: 3413365
CA Cancer J Clin. 2012 Mar-Apr;62(2):75-100
pubmed: 22307864
Nature. 2017 Feb 16;542(7641):313-317
pubmed: 28135720
Eur J Epidemiol. 2021 Apr;36(4):415-428
pubmed: 33492551
Sci Total Environ. 2022 Aug 1;832:154723
pubmed: 35351505
Haematologica. 2018 Nov;103(11):1873-1880
pubmed: 29976736
Science. 1980 Sep 12;209(4462):1197-203
pubmed: 7403879
Br J Cancer. 2016 Feb 16;114(4):388-94
pubmed: 26882064
Epidemiology. 2006 Nov;17(6):604-14
pubmed: 17028502
Lancet. 1956 Sep 1;271(6940):447
pubmed: 13358242
Radiat Res. 2010 Sep;174(3):387-402
pubmed: 20726729
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):114-26
pubmed: 26598533
BMJ Open. 2018 May 14;8(5):e021536
pubmed: 29764888
J Radiol Prot. 2016 Mar;36(1):N1-7
pubmed: 26878249
PLoS One. 2016 Aug 03;11(8):e0160372
pubmed: 27487016
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2207-2217
pubmed: 28368520
Radiat Res. 2020 Sep 16;194(3):259-276
pubmed: 32942303
Radiat Res. 2017 May;187(5):513-537
pubmed: 28319463
Int J Radiat Biol. 2021;97(5):571-592
pubmed: 33787450
Radiat Res. 1999 Feb;151(2):218-24
pubmed: 9952307
J Natl Cancer Inst. 2019 Mar 1;111(3):256-263
pubmed: 30020493
Int J Radiat Biol. 2017 Oct;93(10):1064-1078
pubmed: 28421857
Br J Cancer. 1975 Mar;31(3):271-87
pubmed: 1156514
J Natl Cancer Inst Monogr. 2020 Jul 1;2020(56):188-200
pubmed: 32657347
Lancet Oncol. 2011 May;12(5):416-8
pubmed: 21514885
Clin Exp Allergy. 2008 Aug;38(8):1249-51
pubmed: 18564329
Int J Radiat Biol. 2018 Mar;94(3):272-281
pubmed: 29319401
Radiology. 2009 Apr;251(1):6-12
pubmed: 19332841
PLoS One. 2015 Dec 09;10(12):e0140989
pubmed: 26649569
Radiat Res. 2013 Mar;179(3):361-82
pubmed: 23398354
Br J Cancer. 2017 Jan 3;116(1):126-133
pubmed: 27855443
BMJ. 2010 Jan 14;340:b5349
pubmed: 20075151
Oncogene. 2004 Aug 23;23(38):6404-28
pubmed: 15322514
Int J Radiat Biol. 2021;97(6):769-781
pubmed: 33395329
Int J Cancer. 2010 Jul 15;127(2):412-26
pubmed: 19688829
J Environ Radioact. 2021 Jul;233:106613
pubmed: 33895630
Am J Epidemiol. 1969 Jul;90(1):1-10
pubmed: 5794005
J Clin Med. 2020 Jan 22;9(2):
pubmed: 31979109
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
Health Phys. 2018 Jun;114(6):602-622
pubmed: 29697512
Radiat Res. 1999 May;151(5):626-32
pubmed: 10319736
Environ Health Perspect. 2017 Apr;125(4):714-720
pubmed: 27483500
J Natl Cancer Inst. 2001 Jul 4;93(13):1021-7
pubmed: 11438568
Radiat Res. 2018 Oct;190(4):433-444
pubmed: 30044713
Radiat Res. 2006 Aug;166(2):367-74
pubmed: 16881738
J Radiol Prot. 2014 Mar;34(1):E1-5
pubmed: 24594968
J Clin Endocrinol Metab. 2019 Jan 1;104(1):41-48
pubmed: 30445441
Br J Cancer. 2009 Jan 13;100(1):213-8
pubmed: 19127273
Radiat Res. 1991 Jun;126(3):304-16
pubmed: 2034788
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1208-1217
pubmed: 33827984
Int J Radiat Biol. 2018 Apr;94(4):307-314
pubmed: 29400635
Br J Cancer. 2011 Jan 4;104(1):181-7
pubmed: 21102590
Br J Cancer. 1996 Apr;73(8):1006-12
pubmed: 8611419
Br J Radiol. 1997 Feb;70:130-9
pubmed: 9135438
Pediatr Radiol. 2009 Feb;39 Suppl 1:S4-26
pubmed: 19083224
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):605-13
pubmed: 18349278
J Natl Cancer Inst. 2008 Mar 19;100(6):428-36
pubmed: 18334707
J Environ Radioact. 2021 Nov;238-239:106734
pubmed: 34521026
PLoS One. 2014 Jan 29;9(1):e85723
pubmed: 24489667
Ann ICRP. 2003;33(1-2):5-206
pubmed: 12963090
Int J Radiat Biol. 2021;97(6):782-803
pubmed: 33471563
Radiat Res. 1997 Mar;147(3):385-95
pubmed: 9052687
Radiat Environ Biophys. 2015 Mar;54(1):1-12
pubmed: 25567615
Epidemiology. 2016 May;27(3):e20-1
pubmed: 26841059
J Radiol Prot. 2018 Sep;38(3):1217-1233
pubmed: 30004025
BMJ. 2013 May 21;346:f2360
pubmed: 23694687
PLoS One. 2015 Oct 14;10(10):e0139826
pubmed: 26465339
JAMA. 1990 Aug 1;264(5):585-91
pubmed: 2366297
J Radiol Prot. 2020 Mar;40(1):R1-R23
pubmed: 31751953
J Environ Radioact. 2020 Jan;211:106071
pubmed: 31600676
Leukemia. 2009 Apr;23(4):770-6
pubmed: 19151785
Radiat Environ Biophys. 2017 Nov;56(4):299-328
pubmed: 28939964
Ann ICRP. 2005;35(4):1-140
pubmed: 16782497

Auteurs

Mark P Little (MP)

Radiation Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892-9778, USA. Electronic address: mark.little@nih.gov.

Richard Wakeford (R)

Centre for Occupational and Environmental Health, Faculty of Biology, Medicine and Health, The University of Manchester, Ellen Wilkinson Building, Oxford Road, Manchester M13 9PL, UK.

Simon D Bouffler (SD)

Radiation Effects Department, UK Health Security Agency (UKHSA), Chilton, Didcot OX11 0RQ, UK.

Kossi Abalo (K)

Laboratoire d'Épidémiologie, Institut de Radioprotection et de Sûreté Nucléaire, BP 17, 92262 Fontenay-aux-Roses Cedex, France.

Michael Hauptmann (M)

Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Fehrbelliner Strasse 38, 16816 Neuruppin, Germany.

Nobuyuki Hamada (N)

Radiation Safety Unit, Biology and Environmental Chemistry Division, Sustainable System Research Laboratory, Central Research Institute of Electric Power Industry (CRIEPI), 2-11-1 Iwado-kita, Komae, Tokyo 201-8511, Japan.

Gerald M Kendall (GM)

Cancer Epidemiology Unit, Oxford Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Headington, Oxford, OX3 7LF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH